Follow-The-Filings

Security · featured owners

BBIO Bridgebio Pharma Inc.

Health Care COM Equity as of 2026 Q2 among managers we track

  • 4 Owners
  • Max 3.7%
  • $1.5B
  • 1 new 1 add 2 reduce

BBIO (Bridgebio Pharma Inc.) is held in 4 featured 13F books as of 2026 Q2. Farallon Capital Management is the largest tracked holder by portfolio weight (3.7%). Figures are as-filed 13F, not free float.

Who owns this now

Largest portfolio weights among featured holders · max 3.7% (Farallon Capital Management) · not free-float ownership

  1. Farallon Capital Management add 3.7%
  2. Andreas Halvorsen reduce 2.1%
  3. David Witzke new 0.12%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
Farallon Capital Management 2026 Q2 3.7% Add +14.7% 10,743,063 $800M history
Andreas Halvorsen - Viking Global Investors 2026 Q2 2.1% Reduce −16.0% 9,949,219 $741M history
David Witzke - Avidity Partners Management 2026 Q2 0.12% New 0.12% 10,000 $745K history
Polen Capital Management 2026 Q2 <0.01% Reduce −91.3% 4,002 $298K history

4 current · options excluded

SEC filings

Recent issuer filings from EDGAR · 12 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 8.01,9.01 Filing Doc
8-K 1.01,8.01,9.01 Filing Doc
424B7 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 1.01,3.02,3.03,5.03,7.01,9.01 Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 1.01,1.02,9.01 Filing Doc
10-Q Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 11 rows shown

Filed Form Detail Links
4 Period Aug 18, 2026 Filing Doc
4 Period Aug 16, 2026 · 3 forms Filing Doc
4 Period Jul 30, 2026 Filing Doc
4 Period Jul 9, 2026 · 2 forms Filing Doc
4 Period Jun 22, 2026 · 12 forms Filing Doc
4 Period Jun 20, 2026 Filing Doc
4 Period Jun 15, 2026 Filing Doc
4 Period Jun 4, 2026 Filing Doc
4 Period May 21, 2026 Filing Doc
4 Period May 15, 2026 Filing Doc
4 Period May 16, 2026 Filing Doc

Updated 4 days ago Source: SEC EDGAR submissions All on EDGAR

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $9.3M $221.9M $502.08M
Gross profit * $6.86M $218.02M $481.11M
Gross margin * 73.7% 98.3% 95.8%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $477.59M $720.69M $797.75M
Total non-current assets * $68.79M $198.65M $138.28M
Total assets $546.38M $919.34M $936.02M
Total current liabilities $143.84M $154.4M $287.97M
Total non-current liabilities * $1.75B $2.22B $2.72B
Total equity -$1.35B -$1.47B -$2.09B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$527.72M -$520.73M -$445.91M
Cash from investing $54.03M $60.78M -$24.49M
Cash from financing $451.54M $748.46M $359.29M
Net change in cash -$22.15M $288.51M -$111.1M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders